Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496181 | 0.92 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CHTR2CHTR1A | |
| SCHEMBL9203356 | 0.90 | PTGDR2 (0.41) | ADRA2AADRA2BADRA2CHTR2CHTR1A | |
| SCHEMBL16234728 | 0.87 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CGBA1HTR2C | |
| Hydrochloric Acid SCHEMBL4676075 | 0.86 | HTR2C (0.57) | ADRA2AADRA2BADRA2CHTR2CHTR1A | |
| SCHEMBL15704287 | 0.82 | CHRNB4 (0.48) | ADRA2AADRA2BADRA2CHTR2CSLC6A2 | |
| SCHEMBL4680009 | 0.81 | MEN1 (0.46) | CHRM1CHRM4KCNH2 | |
| SCHEMBL20241552 | 0.79 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CGBA1HTR2C | |
| SCHEMBL14300266 | 0.78 | PTGS2 (0.40) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 | |
| SCHEMBL20595810 | 0.77 | PRCP (0.39) | ADRA2AADRA2BADRA2CHTR2CGABRA1 | |
| SCHEMBL21784784 | 0.77 | MMP2 (0.42) | ADRA2AADRA2BADRA2CGBA1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-08-23 | — | — | US | disclosed |
| EP-3331863-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2018-06-13 | — | — | EP | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
| WO-2017021879-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | ADRA2A 179/4885ADRA2B 120/4885ADRA2C 217/4885 |
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | ADRA2A 179/4885ADRA2B 120/4885ADRA2C 217/4885 |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | ADRA2A 190/4885ADRA2B 120/4885ADRA2C 237/4885 |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | ADRA2A 473/4885ADRA2B 289/4885ADRA2C 513/4885 |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | ADRA2A 190/4885ADRA2B 120/4885ADRA2C 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.